文献速递间质性肺疾病

纵隔淋巴结评估预测间质性肺疾病预后:观察性队列研究及独立验证

Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

该观察性队列研究评估了胸部CT纵隔淋巴结(MLN)增大对间质性肺疾病(ILD)患者临床结局的预测价值。在1,094例ILD患者中,66%存在MLN增大(≥10 mm),其与无移植生存期(TFS)降低及全因和呼吸相关住院风险升高独立相关,并伴有肺功能下降和血浆可溶性CD40L水平降低。外部数据集独立分析验证了上述发现。

要点

  • ILD患者胸部CT纵隔淋巴结增大(≥10 mm)与无移植生存期缩短及住院风险增加相关。
  • MLN增大患者肺功能更低,血浆可溶性CD40L浓度降低。
  • 血浆IL-10 >45 pg/ml预测死亡风险升高,MLN与细胞因子或可改善预后模型。

核心结论

  • 纵隔淋巴结增大可预测ILD患者的无移植生存期和住院风险。
  • 纵隔淋巴结增大与循环可溶性CD40L水平降低相关。
  • 将纵隔淋巴结和细胞因子纳入现有预测模型可能改善ILD预后评估。

研究设计与样本

  • 观察性队列研究,纳入10年间基线评估的ILD患者,排除结节病和药物毒性相关ILD。
  • 共评估1,094例患者胸部CT(平均年龄64岁,52%男性),并在三个独立ILD队列中评估结局。

主要发现

  • 纵隔淋巴结增大(≥10 mm)见于66%(n=726)的患者。
  • 与MLN<10 mm者相比,MLN增大者无移植生存期风险比HR为1.53(95%CI 1.12-2.10,P=0.008)。
  • MLN增大者全因住院发生率比IRR为1.52(95%CI 1.17-1.98,P=0.002),呼吸住院IRR为1.71(95%CI 1.15-2.53,P=0.008)。
  • MLN增大者肺功能更低,血浆可溶性CD40L浓度为376 pg/ml vs. 505 pg/ml(P=0.001)。
  • 血浆IL-10浓度>45 pg/ml预测死亡风险HR为4.21(95%CI 1.21-14.68,P=0.024)。

关键数值与推荐

  • 纵隔淋巴结增大定义为直径≥10 mm。
  • 血浆IL-10浓度>45 pg/ml作为预测死亡风险的阈值。

临床怎么用

  • 在ILD患者基线胸部CT评估中应关注纵隔淋巴结大小,≥10 mm提示预后较差。
  • 纵隔淋巴结增大患者需更密切监测肺功能、住院风险及无移植生存。
  • 可考虑结合血浆可溶性CD40L和IL-10等细胞因子指标优化风险分层。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Mediastinal lymph node (MLN) enlargement on chest computed tomography (CT) is prevalent in patients with interstitial lung disease (ILD) and may reflect immunologic activation and subsequent cytokine-mediated immune cell trafficking. OBJECTIVES: We aimed to determine whether MLN enlargement on chest CT predicts clinical outcomes and circulating cytokine levels in ILD. METHODS: MLN measurements were obtained from chest CT scans of patients with ILD at baseline evaluation over a 10-year period. Patients with sarcoidosis and drug toxicity-related ILD were excluded. MLN diameter and location were assessed. Plasma cytokine levels were analyzed in a subset of patients. The primary outcome was transplant-free survival (TFS). Secondary outcomes included all-cause and respiratory hospitalizations, lung function, and plasma cytokine concentrations. Cox regression was used to assess mortality risk. Outcomes were assessed in three independent ILD cohorts. MEASUREMENTS AND MAIN RESULTS: Chest CT scans were assessed in 1,094 patients (mean age, 64 yr; 52% male). MLN enlargement (≥10 mm) was present in 66% (n = 726) and strongly predicted TFS (hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.12-2.10; P = 0.008) and risk of all-cause and respiratory hospitalizations (internal rate of return [IRR], 1.52; 95% CI, 1.17-1.98; P = 0.002; and IRR, 1.71; 95% CI, 1.15-2.53; P = 0.008, respectively) when compared with subjects with MLN <10 mm. Patients with MLN enlargement had lower lung function and decreased plasma concentrations of soluble CD40L (376 pg/ml vs. 505 pg/ml, P = 0.001) compared with those without MLN enlargement. Plasma IL-10 concentration >45 pg/ml predicted mortality (HR, 4.21; 95% CI, 1.21-14.68; P = 0.024). Independent analysis of external datasets confirmed these findings. CONCLUSIONS: MLN enlargement predicts TFS and hospitalization risk in ILD and is associated with decreased levels of a key circulating cytokine, soluble CD40L. Incorporating MLN and cytokine findings into current prediction models might improve ILD prognostication.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Adegunsoye A, Oldham JM, Bonham C, et al. Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation. Am J Respir Crit Care Med. 2019. PMID: 30216085. doi:10.1164/rccm.201804-0761OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。